Liver Disease in the Pharmacy: Recognising Risk and Knowing When to Refer
How to identify patients at risk of undiagnosed liver disease, which symptoms require urgent action, and how to navigate referral pathways for MASLD, cirrhosis, viral hepatitis, and drug-induced liver injury.
Why this matters
Liver disease causes approximately 10,000 deaths per year in England, and the UK has one of the highest rates of liver disease mortality in Western Europe. Unlike most other major organ diseases, liver disease mortality has risen significantly over recent decades. The three most common causes are alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease), and chronic viral hepatitis due to hepatitis B or C infection.
Many patients with significant liver fibrosis or even compensated cirrhosis have few or no symptoms. By the time jaundice, ascites, or a variceal haemorrhage develops, the disease has usually progressed to a late and potentially irreversible stage. This means that relying on symptoms alone to identify at-risk patients will miss most cases. The most valuable work happens earlier: recognising which patients collecting prescriptions have unaddressed risk factors and have not been assessed.
Community pharmacists are well placed to do this. Patients with type 2 diabetes, metabolic syndrome, or obesity collect repeat prescriptions regularly, often for years, without ever receiving a liver disease review. Patients taking potentially hepatotoxic medicines need periodic monitoring, and the pharmacist is well positioned to check whether that monitoring is in place. When symptoms do appear, knowing whether they represent a 999 emergency, a same-day referral, or a routine GP conversation can directly influence the outcome.
One practical illustration: a 58-year-old man collecting metformin and atorvastatin mentions over several months that he is getting more tired and that his waistband feels tighter. He attributes this to getting older. On the day he asks for a recommendation for wind relief, the pharmacist notices his abdomen looks distended and he is slightly pale. He is advised to contact his GP the same day for assessment of possible ascites. He is subsequently found to have cirrhosis secondary to MASLD, previously unsuspected. Cases like this are not unusual in community pharmacy.
Red flags vs more likely benign
| Feature | More likely benign | Red flag ⚠ |
|---|---|---|
| Skin and sclera | Normal skin and eye colour | Yellowing of the skin or whites of the eyes (jaundice): always requires prompt assessment |
| Urine and stools | Normal urine and stool colour | Dark tea-coloured urine and pale or grey stools alongside jaundice: suggests cholestasis or biliary obstruction |
| Itching (pruritus) | Mild, localised, with a clear skin cause | Persistent generalised itch without a skin rash, particularly at night: a recognised feature of cholestatic liver disease; patients often present requesting antihistamines or emollients without making the link |
| Abdomen | No swelling; mild discomfort without distension | Visible abdominal swelling (possible ascites), right upper quadrant tenderness, or a noticeably enlarged and tender liver |
| Gastrointestinal bleeding | No blood in vomit or stool | Vomiting blood or passing black tarry stools (melaena): possible variceal haemorrhage; call 999 immediately |
| Mental state | Alert, orientated, and behaving normally | Confusion, drowsiness, altered behaviour, or slurred speech in a patient with known liver disease: possible hepatic encephalopathy |
| Bleeding tendency | No unusual bruising or prolonged bleeding | Easy bruising, spontaneous bleeding, or prolonged bleeding from minor cuts in a patient who is also jaundiced or unwell: possible coagulopathy in acute liver failure |
| Weight and appetite | Mild fluctuation; short-term appetite change during illness | Progressive unintentional weight loss with persistent fatigue, poor appetite, or upper abdominal discomfort |
| Physical signs | An incidental single spider naevus on the face or chest is common in healthy adults and not necessarily significant | More than five spider naevi, pronounced palmar erythema (redness of both palms), caput medusae, or marked muscle wasting of the temples or upper limbs |
| Medicines and liver tests | Stable liver blood results on a long-established medicine with no new symptoms | New rise in liver enzymes, or new jaundice, after starting or dose-increasing a potentially hepatotoxic medicine: possible drug-induced liver injury (DILI) |
Identifying patients at increased risk: who to flag for GP review
Significant liver disease can be present without any symptoms. The pharmacist's role is to recognise patients with established risk factors who have not been assessed, and to prompt review before complications develop.
- Type 2 diabetes and metabolic syndrome: NICE NG49 recommends clinicians be aware that MASLD is more common in people with type 2 diabetes or metabolic syndrome. Ask whether the patient has had any recent liver disease assessment. Many patients in this group are never assessed despite the established link.
- Obesity (body mass index of 30 kg/m2 or above): a recognised risk factor for cirrhosis in NICE NG50. Sustained weight loss through diet and regular exercise remains the cornerstone of MASLD management, and the pharmacist can reinforce this at every interaction. GLP-1 receptor agonists (such as semaglutide) are increasingly used in MASLD management and may be encountered in prescriptions.
- Significant alcohol use: ask about weekly units during medicines review. The Chief Medical Officers advise both men and women to drink no more than 14 units per week regularly. Drinking consistently above this level increases liver disease risk; NICE NG50 uses thresholds of 50 or more units per week in men and 35 or more in women to trigger cirrhosis screening. The AUDIT-C questionnaire (three validated questions about frequency, quantity, and heavy drinking occasions) is a practical counter-based screening tool. Caution: patients with established alcohol dependence should seek medical support before attempting to stop drinking abruptly, as alcohol withdrawal can be life-threatening.
- Viral hepatitis risk: several groups are at elevated risk and warrant GP referral for testing if unscreened. These include: anyone with a history of injecting drug use, even once; people who have been imprisoned; those experiencing homelessness; people who received blood products or organ transplants before universal screening was introduced; those born in or who have received healthcare in countries with high hepatitis B or C prevalence (including sub-Saharan Africa, south-east Asia, eastern Europe, and central Asia); and those who have had close household or sexual contact with a known carrier. Effective curative treatments now exist for hepatitis C, with cure rates above 95%.
- Hepatitis B vaccination: when identifying patients at risk of hepatitis B (household contacts of a known carrier, people who inject drugs, men who have sex with men, and certain occupational or travel risk groups), consider that hepatitis B vaccination may be indicated and has not been offered. This is a straightforward intervention the GP can arrange.
- Potentially hepatotoxic medicines: several commonly dispensed drugs carry a risk of liver injury. Examples include: methotrexate (requires regular liver blood test monitoring and fibrosis surveillance with long-term use); amiodarone (progressive liver damage can occur even years into treatment); sodium valproate; nitrofurantoin on long-term use; isoniazid; and prolonged courses of non-steroidal anti-inflammatory drugs (NSAIDs). Ask patients directly about herbal and traditional medicines. Specific products associated with significant liver injury include green tea extract supplements, kava, black cohosh, and a range of traditional Chinese and Ayurvedic preparations. Bodybuilding supplements (particularly products containing anabolic agents) are a growing cause of serious drug-induced liver injury. Check whether liver blood test monitoring is current for any patient on a hepatotoxic medicine. If there is no documented recent result, prompt a GP review rather than assuming monitoring is in place.
Normal liver blood tests do not rule out significant liver disease. NICE NG49 is explicit: routine liver blood tests should not be used to exclude MASLD or to assess for advanced fibrosis.
Non-invasive liver fibrosis assessment: what happens in primary care
When a patient with metabolic or other risk factors is identified, regardless of whether liver enzymes are normal or abnormal, primary care pathways use non-invasive tools to risk-stratify before considering referral.
- Enhanced Liver Fibrosis (ELF) test: NICE NG49 recommends the ELF test as the preferred tool for assessing advanced fibrosis in people with MASLD. An ELF score of 10.51 or above indicates advanced liver fibrosis and should prompt referral to hepatology. Patients with an ELF score below 10.51 are unlikely to have advanced fibrosis and should be reassessed every three years. Interpretation should always follow local pathways, which may differ from the NICE threshold.
- FIB-4 index: many NHS primary care pathways use the FIB-4 index as a first-step triage tool before ELF testing, because it can be calculated from routine blood results (age, alanine aminotransferase [ALT], aspartate aminotransferase [AST], and platelet count) at no additional cost. A score below 1.30 makes advanced fibrosis unlikely; a score above 2.67 indicates higher risk. Age-adjusted thresholds apply: the lower cutoff of 2.0 is used for patients over 65 years, as FIB-4 rises with age independently of liver disease. Local pathways vary considerably and the pharmacist should defer to the GP's interpretation.
- Transient elastography (FibroScan): used in secondary care to measure liver stiffness as a direct marker of fibrosis. Patients referred with a high FIB-4 or ELF score will typically undergo this assessment before a liver biopsy is considered.
- Hepatocellular carcinoma (HCC) surveillance: all patients with confirmed cirrhosis should be under specialist hepatology review. NICE NG50 recommends six-monthly liver ultrasound surveillance for hepatocellular carcinoma in all patients with cirrhosis. If a patient with known cirrhosis mentions they have not had a scan recently, it is worth checking that they remain engaged with their hepatology follow-up and surveillance programme.
The pharmacist's role is not to calculate or interpret these scores. It is to ensure that patients with recognised risk factors are being monitored, to prompt GP review when they are not, and to act on symptoms without delay.
What to do in pharmacy
Key takeaways
- Many patients with significant liver fibrosis or early cirrhosis have no symptoms. Normal liver blood tests do not exclude significant disease (NICE NG49 and NG50). Use metabolic risk factors, alcohol history, medication review, and viral hepatitis risk to identify who needs GP assessment.
- New jaundice in any patient requires same-day urgent assessment. Confusion or drowsiness in a patient with known liver disease requires 999 or urgent same-day review for hepatic encephalopathy. Vomiting blood or melaena is a 999 emergency.
- Persistent generalised pruritus without a visible skin rash is a recognised feature of cholestatic liver disease. When a patient requests antihistamines or emollients for unexplained itching, ask specifically about jaundice, dark urine, and pale stools before recommending over-the-counter treatment.